BDSX - Company ID 0001439725
BIODESIX INC trades as BDSX. In its fiscal 2025 annual report the company posted revenue of $88.50M, up 24.1% from the prior year and net income of -$35.27M. This page tracks BIODESIX INC through 586 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years BIODESIX INC's revenue grew from $24.55M to $88.50M, a compound annual growth rate of 23.8%. Net profit margin expanded from -125.1% to -39.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Securities registration | S-3 | 2026-05-21 |
| Major company event | 8-K | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-08 |
| Quarterly report | 10-Q | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-28 |
| Annual report to shareholders | ARS | 2026-04-09 |
The largest companies sharing BIODESIX INC's SEC industry classification (services-medical laboratories).
BIODESIX INC reported revenue of $88.50M for fiscal year 2025, an increase of 24.1% year over year.
In its latest fiscal year BIODESIX INC reported a net loss of $35.27M.